Testicular cancer patients needed for landmark treatment reduction study
NCT ID NCT06309745
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing whether giving less treatment (de-escalation) to men with stage II seminoma testicular cancer is safe and improves quality of life. Researchers will enroll 30 men at two UK hospitals to see if patients are willing to join and how their cancer and well-being are affected. The goal is to gather information needed to design a larger, more definitive trial.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEMINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Barts and London Hospital NHS Trust
RECRUITINGLondon, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- High-Dose chemo with stem cell transplant tested against standard therapy for tough germ cell cancers
- New proton beam study aims to cut cancer treatment side effects
- Testicular cancer treatment: which is easier on patients?
- Blood marker may predict cancer return in testicular tumor patients
- Immunotherapy duo takes on resistant germ cell tumors
- Can less be more? new trial aims to reduce side effects in testicular cancer treatment